0001493152-24-015404.txt : 20240422 0001493152-24-015404.hdr.sgml : 20240422 20240419174836 ACCESSION NUMBER: 0001493152-24-015404 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240418 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240422 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORAGENICS INC CENTRAL INDEX KEY: 0001174940 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 593410522 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32188 FILM NUMBER: 24859082 BUSINESS ADDRESS: STREET 1: 1990 MAIN STREET STREET 2: SUITE 750 CITY: SARASOTA STATE: FL ZIP: 34236 BUSINESS PHONE: 8132867900 MAIL ADDRESS: STREET 1: 1990 MAIN STREET STREET 2: SUITE 750 CITY: SARASOTA STATE: FL ZIP: 34236 8-K 1 form8-k.htm
false 0001174940 0001174940 2024-04-18 2024-04-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

 

Date of Report: April 18, 2024

(Date of earliest event reported)

 

 

 

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

FL   001-32188   59-3410522

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

1990 Main Street

Suite 750

Sarasota, FL

   34236
(Address of principal executive offices)   (Zip Code)

 

813-286-7900

(Registrant’s telephone number, including area code)

 

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   OGEN   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.

 

On April 18, 2024, Oragenics, Inc. (the “Company”) received notification (the “Notice”) from the NYSE American LLC (the “NYSE American”) that the Company is no longer in compliance with NYSE American’s continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’ equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Company reported stockholders equity of $3.2 million as of December 31, 2023, and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2023.

 

The Notice further provides that the Company must submit a plan of compliance (the “Plan”) by May 18, 2024 addressing how it intends to regain compliance with the continued listing standards by October 18, 2025. The Plan is required to include specific milestones, quarterly financial projections and details related to any strategic initiatives the Company plans to complete.

 

The Company has begun to prepare its Plan for submission to the NYSE American by the May 18, 2024 deadline. If the NYSE American accepts the Company’s Plan, the Company will be able to continue its listing during the Plan period and will be subject to continued periodic review by the NYSE American staff. If the Plan is not submitted, or not accepted, or is accepted but the Company is not in compliance with the continued listing standards by October 18, 2025 or if the Company does not make progress consistent with the Plan during the Plan period, the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide.

 

The Company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE American’s requirements. However, there can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required timeframe.

 

The Notice has no immediate impact on the listing of the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”), which will continue to be listed and traded on the NYSE American during this period, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Common Stock will continue to trade under the symbol “OGEN”, but will have an added designation of “.BC” to indicate the status of the Common Stock as “below compliance”. The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission.

 

If the Common Stock ultimately were to be delisted for any reason, it could negatively impact the Company by (i) reducing the liquidity and market price of the Company’s Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock, which could negatively impact the Company’s ability to raise equity financing; and (iii) limiting the Company’s ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets; and (iv) impairing the Company’s ability to provide equity incentives to its employees.

 

ITEM 8.01 OTHER EVENTS.

 

On April 19, 2024, in accordance with the NYSE American’s procedures, the Company issued a press release discussing the matters disclosed in Item 3.01 above. A copy of the press release is included herewith as Exhibit 99.1, which is incorporated by reference into this Item 8.01.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release Dated, April 19, 2024.
     
104   Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

 

 
 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 19th day of April, 2024.

 

  ORAGENICS, INC.
  (Registrant)
     
  BY: /s/ Janet Huffman
    Janet Huffman
    Chief Financial Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

 

 

 

April 19, 2024

 

SARASOTA, Fla.—(BUSINESS WIRE)— Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’ equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Company reported a stockholders’ equity of $3.2 million as of December 31, 2023, and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2023.

 

The Notice has no immediate impact on the listing of the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”), which will continue to be listed and traded on the NYSE American during the Plan period, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Common Stock will continue to trade under the symbol “OGEN”, but will have an added designation of “.BC” to indicate the status of the Common Stock as “below compliance”. The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission.

 

The Company must submit a plan of compliance (the “Plan”) by May 18, 2024 addressing how it intends to regain compliance with Sections 1003(a)(ii) and (iii) of the Company Guide by October 18, 2025. The Company has begun to prepare its Plan for submission to the NYSE American by the May 18, 2024 deadline.

 

If the NYSE American accepts the Company’s plan, the Company will be able to continue its listing during the Plan period and will be subject to continued periodic review by the NYSE American staff. If the Plan is not submitted, or not accepted, or is accepted but the Company is not in compliance with the continued listing standards by October 18, 2025 or if the Company does not make progress consistent with the Plan during the plan period, the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide.

 

The Company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE American’s requirements. However, there can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required timeframe.

 

About Oragenics

 

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.

 

 
 

 

Forward-Looking Statements

 

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including with regard to the Company ability to timely submit its Plan to the NYSE American, the acceptance of its Plan by the NYSE American and the Company’s ability to regain compliance with the NYSE American’s continued listing standards by October 18, 2025. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

 

Oragenics, Inc.
Janet Huffman, Chief Financial Officer
813-286-7900
jhuffman@oragenics.com

 

LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com

 

 

 

 

 EX-101.SCH 3 ogen-20240418.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ogen-20240418_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ogen-20240418_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 18, 2024
Entity File Number 001-32188
Entity Registrant Name Oragenics, Inc.
Entity Central Index Key 0001174940
Entity Tax Identification Number 59-3410522
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 1990 Main Street
Entity Address, Address Line Two Suite 750
Entity Address, City or Town Sarasota
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34236
City Area Code 813
Local Phone Number 286-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OGEN
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://oragenics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ogen-20240418.xsd ogen-20240418_lab.xml ogen-20240418_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "OGEN", "nsuri": "http://oragenics.com/20240418", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ogen-20240418.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ogen-20240418_lab.xml" ] }, "presentationLink": { "local": [ "ogen-20240418_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://oragenics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://oragenics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-015404-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-015404-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001174940 2024-04-18 2024-04-18 iso4217:USD shares iso4217:USD shares false 0001174940 8-K 2024-04-18 Oragenics, Inc. FL 001-32188 59-3410522 1990 Main Street Suite 750 Sarasota FL 34236 813 286-7900 false false false false Common Stock OGEN NYSEAMER false